Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2021 from OUS - Experimental Immunotherapy (Olweus)

6 publications found

Ask EH, Tschan-Plessl A, Gjerdingen TJ, Saetersmoen ML, Hoel HJ, Wiiger MT, Olweus J, Wahlin BE, Lingjaerde OC, Horowitz A, Cashen AF, Watkins M, Fehniger TA, Holte H, Kolstad A, Malmberg KJ (2021)
A Systemic Protein Deviation Score Linked to PD-1(+) CD8(+) T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma
Med, 2 (2), 180-+
DOI 10.1016/j.medj.2020.10.006

Maclachlan KH, Rustad EH, Derkach A, Zheng-Lin B, Yellapantula V, Diamond B, Hultcrantz M, Ziccheddu B, Boyle EM, Blaney P, Bolli N, Zhang Y, Dogan A, Lesokhin AM, Morgan GJ, Landgren O, Maura F (2021)
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
Nat Commun, 12 (1), 5172
DOI 10.1038/s41467-021-25469-8, PubMed 34453055

Maura F, Boyle EM, Rustad EH, Ashby C, Kaminetzky D, Bruno B, Braunstein M, Bauer M, Blaney P, Wang Y, Ghamlouch H, Williams L, Stoeckle J, Davies FE, Walker BA, Maclachlan K, Diamond B, Landgren O, Morgan GJ (2021)
Chromothripsis as a pathogenic driver of multiple myeloma
Semin Cell Dev Biol (in press)
DOI 10.1016/j.semcdb.2021.04.014, PubMed 33958284

Mazzarella L, Enblad G, Olweus J, Malmberg KJ, Jerkeman M (2021)
Advances in immune therapies in hematological malignancies
J Intern Med
DOI 10.1111/joim.13395, PubMed 34624160

Mester S, Evers M, Meyer S, Nilsen J, Greiff V, Sandlie I, Leusen J, Andersen JT (2021)
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
MAbs, 13 (1), 1893888
DOI 10.1080/19420862.2021.1893888, PubMed 33691596

Rustad EH, Nadeu F, Angelopoulos N, Ziccheddu B, Bolli N, Puente XS, Campo E, Landgren O, Maura F (2021)
mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies
Commun Biol, 4 (1), 424
DOI 10.1038/s42003-021-01938-0, PubMed 33782531

 
Page visits: 656265